Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

Conventional type 1 dendritic cells (cDC1s) are superior in antigen cross-presentation and priming CD8+ T cell anti-tumor immunity and thus, are a target of high interest for cancer immunotherapy. Type I interferon (IFN) is a potent inducer of antigen cross-presentation, but, unfortunately, shows on...

Full description

Bibliographic Details
Main Authors: Paul Noe, Joy H. Wang, Kyu Chung, Zhiyong Cheng, Jessica J. Field, Xiaomeng Shen, Stephanie C. Casey, Christa L. Cortesio, Cinthia V. Pastuskovas, Hyewon Phee, Kristin V. Tarbell, Jackson G. Egen, Amy-Jo Casbon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
immunogenicity
interferon
immunotherapy
dendritic cells
conventional type I DCs
antibody IFN fusion
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272055/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272055/full

Similar Items